Show simple item record

dc.contributor.authorWisløff, Torbjørnen_US
dc.contributor.authorSelmer, Randi M.en_US
dc.contributor.authorHalvorsen, Sigrunen_US
dc.contributor.authorFretheim, Atleen_US
dc.contributor.authorNorheim, Ole Frithjofen_US
dc.contributor.authorKristiansen, Ivar Sønbøen_US
dc.date.accessioned2014-08-29T13:31:59Z
dc.date.available2014-08-29T13:31:59Z
dc.date.issued2012-04-04eng
dc.identifier.issn1471-2261
dc.identifier.urihttps://hdl.handle.net/1956/8379
dc.description.abstractBackground: Hypertension is one of the leading causes of cardiovascular disease (CVD). A range of antihypertensive drugs exists, and their prices vary widely mainly due to patent rights. The objective of this study was to explore the cost-effectiveness of different generic antihypertensive drugs as first, second and third choice for primary prevention of cardiovascular disease. Methods: We used the Norwegian Cardiovascular Disease model (NorCaD) to simulate the cardiovascular life of patients from hypertension without symptoms until they were all dead or 100 years old. The risk of CVD events and costs were based on recent Norwegian sources. Results: In single-drug treatment, all antihypertensives are cost-effective compared to no drug treatment. In the base-case analysis, the first, second and third choice of antihypertensive were calcium channel blocker, thiazide and angiotensin-converting enzyme inhibitor. However the sensitivity and scenario analyses indicated considerable uncertainty in that angiotensin receptor blockers as well as, angiotensin-converting enzyme inhibitors, beta blockers and thiazides could be the most cost-effective antihypertensive drugs. Conclusions: Generic antihypertensives are cost-effective in a wide range of risk groups. There is considerable uncertainty, however, regarding which drug is the most cost-effective.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/eng
dc.titleChoice of generic antihypertensive drugs for the primary prevention of cardiovascular disease - A cost-effectiveness analysisen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2013-08-23T09:20:59Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2012 Wisløff et al; licensee BioMed Central Ltd.
dc.rights.holderTorbjørn Wisløff et al.; licensee BioMed Central Ltd.
dc.source.articlenumber26
dc.identifier.doihttps://doi.org/10.1186/1471-2261-12-26
dc.identifier.cristin949827
dc.source.journalBMC Cardiovascular Disorders
dc.source.4012


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY